Claims for Patent: 10,835,527

Summary for Patent: 10,835,527

Title:	Compositions and methods for reducing major adverse cardiovascular events
Abstract:	The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.
Inventor(s):	Preston Klassen, Kristin Taylor
Assignee:	Nalpropion Pharmaceuticals LLC
Application Number:	US16/356,663
Patent Claims:	1. A method of treating overweight or obesity in a subject having an increased risk of adverse cardiovascular outcomes, the method comprising: treating the subject for overweight or obesity by administering to the subject a daily dose of 4-50 mg of naltrexone, or a pharmaceutically acceptable salt thereof, and 50-400 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks. 2. The method of claim 1, wherein the subject is a current smoker that does not have type-two diabetes. 3. The method of claim 1, wherein the subject was administered: about 8 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a first week of treatment; about 16 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 180 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a second week of treatment; about 24 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a third week of treatment; and about 32 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 360 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a fourth week of treatment and any subsequent weeks of treatment. 4. The method of claim 1, wherein the period of treatment is at least 20 weeks. 5. The method of claim 2, wherein the subject was administered: about 8 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a first week of treatment; about 16 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 180 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a second week of treatment; about 24 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a third week of treatment; and about 32 mg of naltrexone or a pharmaceutically acceptable salt thereof and about 360 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a fourth week of treatment and any subsequent weeks of treatment. 6. The method of claim 2, wherein the period of treatment is at least 20 weeks. 7. The method of claim 1, wherein the subject has type-two diabetes. 8. The method of claim 7, wherein the subject has had type-two diabetes for less than 6 years. 9. The method of claim 1, wherein the subject is a current smoker. 10. The method of claim 1, wherein the subject has a history of cardiovascular disease. 11. The method of claim 10, wherein the subject has one or more of: a history of documented myocardial infarction more than 3 months prior to treatment; a history of coronary, carotid or peripheral revascularization; angina with ischemic changes, ECG changes on a graded exercise test; positive cardiac imaging study; ankle brachial index less than 0.9 within 2 years prior to treatment; or greater than 50% stenosis of a coronary, carotid, or lower extremity artery within 2 years prior to treatment. 12. The method of claim 1, wherein administering the sustained release naltrexone or a pharmaceutically acceptable salt thereof and sustained release bupropion or a pharmaceutically acceptable salt thereof decreases the subject's risk of a major adverse cardiovascular outcome. 13. The method of claim 7, wherein administering the naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof decreases the subject's risk of a major adverse cardiovascular outcome. 14. The method of claim 8, wherein administering the naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof decreases the subject's risk of a major adverse cardiovascular outcome. 15. The method of claim 9, wherein administering the naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof decreases the subject's risk of a major adverse cardiovascular outcome. 16. The method of claim 1, wherein the adverse cardiovascular outcome is selected from the group consisting of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. 17. The method of claim 12, wherein the adverse cardiovascular outcome is selected from the group consisting of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. 18. The method of claim 13, wherein the adverse cardiovascular outcome is selected from the group consisting of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. 19. The method of claim 14, wherein the adverse cardiovascular outcome is selected from the group consisting of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. 20. The method of claim 15, wherein the adverse cardiovascular outcome is selected from the group consisting of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.